Invivogen
Menu

Bispecific antibody against human BCMA and β-Gal - Negative control

Product Unit size Cat. code Docs. Qty. Price

Anti-hBCMA-βGal

Bispecific antibody against human BCMA and β-galactosidase; Negative control

Show product

10 µg

5 x 10 µg

bimab-bcmabg-01
+-
$109
  • About
  • Specifications
  • Contents
  • Related products

Anti-hBCMA-βGal binds to hBMCA on B cells but not to hCD3 on T cells
Anti-hBCMA-βGal binds to hBCMA on B cells but not to CD3 on T cells

Monoclonal scFv antibody against human BCMA and β-galactosidase; Negative control

Anti-hBCMA-βGal is a bispecific antibody that binds to two sites: human B cell maturation antigen (hBCMA) and E. coli β-galactosidase (β-Gal). It is used as a negative control for Anti-hBCMA-CD3 bispecific antibody that, like pacanalotamab, engages unstimulated T cells to proliferate and exert cytotoxic activity on BCMA-positive myeloma cells [1].

The human BCMA (also known as CD269 or TNFRSF17) plays a central role in B cell maturation and differentiation towards plasma cells [2]. It is expressed on plasma cells, mature B cells as well as multiple myeloma cells. By interacting with its ligands, hBCMA activates several pathways promoting B cell survival and proliferation but also tumor cell growth and drug resistance [2-3].
 

Key features

  • Reacts with human BCMA
  • Unable to interact with human CD3
  • ScFv of clinical relevant bispecific mAb pacanalotamab
  • Hexahistidine (His6) tag
  • Provided azide-free
  • Each lot is functionally tested

 

References:

1. Topp et al., 2020. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783.
2. Hosny et al., 2021. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J Clin Med. Oct 6;10(19):4593.
3. Abramson et al., 2020. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci. 2020;21(15):5192.  

Figures

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-hBCMA-βgal
Absence of Jurkat-Lucia™ NFAT cell activation using Anti-hBCMA-βgal
Evaluation of T cell activation
Evaluation of T cell activation

Dose-dependent activation of Jurkat-Lucia™ NFAT cells with Anti-hBCMA-CD3 in the presence of Raji cells expressing hBCMA. Raji cells, expressing hBCMA were pre-incubated with increasing concentrations of Anti-hBCMA-CD3 or Anti-hBCMA-bGal (negative control) for 30 minutes before the addition of Jurkat-Lucia™ NFAT cells. After 24 hours of incubation, T cell activation was determined by measuring the Lucia luciferase activity using QUANTI-Luc™ detection reagent. Results are presented as fold change over non-induced cells (mean ± SEM).

Back to the top

Specifications

Clonality: Monoclonal bispecific antibody.

Specificity: Targets human BCMA and E. coli β-galactosidase (β-Gal).

Isotype: none (scFv).

Source: CHO (Chinese hamster ovary) cells.

Purity: >90%. Purified by affinity chromatography.

Quality control:

  •    Binding to hBCMA has been confirmed by flow cytometry.
  •    The inability of Anti-hBCMA-βGal to bind to hCD3 has been confirmed using ELISA.
  •    The complete sequence of this antibody has been verified.
  •    The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top

Contents

Anti-hBCMA-βGal purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • bimab-bcmabg-01: 10 µg
  • bimab-bcmabg-05: 5 x 10 µg

Product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20°C.

stable"/ Lyophilized product is stable for at least 1 year.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty